biomarin pharmaceutical inc bmrn reported a q2 adjusted eps of 054 higher than 041 a year ago and beating the consensus of 047 the companys revenue rose 12 to 5953 million beating the consensus of 51891 million voxzogo drug sales increased 229 to 1133 million due to continued global expansion and rapid patient uptake across all regions over 2000 were being treated with commercial voxzogo globally pivotal program with voxzogo in a new potential second indication hypochondroplasia to start in q4 of 2023 palynziq product revenues increased 22 to 749 million primarily due to new patients initiating therapy naglazyme product revenues declined 22 to 901 million primarily driven by the timing of orders in countries that place large government orders particularly in latin america also read biomarins roctavian us launch focus on commercial strategy amid eu failures analyst points out for the remainder of 2023 we plan to build on the foundation of growth and profitability achieved in the first half of the year expand voxzogo globally and treat the first roctavian patients in the us and europe said jeanjacques bienaimé chairman and ceo of biomarin guidance biomarin has upped its fy23 voxzogo sales forecast to 400 million440 million from 380 million430 million the company reaffirms fy23 revenue guidance of 2375 billion  25 billion versus the consensus of 246 billion it updated the adjusted eps outlook to 185  210 from 180  205 versus the consensus of 102 price action bmrn shares are down 036 at 8761 premarket on the last check tuesday